Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Sarepta Therapeutics (SRPT)

Sarepta settles REGENXBIO, UPenn patent litigation with $39.0 million payment

Neutral Impact 3 of 5 legal/regulatory Written later

Sarepta Therapeutics entered a settlement agreement with REGENXBIO, the Trustees of the University of Pennsylvania and Catalent to resolve pending patent infringement litigation and an related appeal over several patents. Sarepta will pay REGENXBIO a lump sum of $39.0 million, an amount it had already recorded as a litigation contingency charge in the second quarter of 2026. The settlement releases Sarepta from past infringement claims and includes covenants not to sue for ELEVIDYS and other AAVrh74-based products, which removes a source of legal uncertainty for shareholders.

Key points

  • Sarepta will pay REGENXBIO a $39.0 million lump sum within ten days of the September 23, 2026 Effective Date.
  • The $39.0 million matches a litigation contingency charge recorded in the three and six months ended June 30, 2026.
  • REGENXBIO and UPenn released claims up to the Effective Date and agreed not to sue over ELEVIDYS and other AAVrh74-based products under the UPenn Patents.
  • The Litigations will be dismissed with prejudice, and the settlement includes no admission of liability.

The filing

CompanySarepta Therapeutics (SRPT)
Form8-K, current report
Filed with the SECSep 23, 2026, 4:13 PM ET
Accession number0001193125-26-399416

Items reported: 1.01 Material Definitive Agreement

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:55 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 23, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.